Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Esperion Therapeutics Inc (ESPR), Cempra Inc (CEMP), Zeltiq Aesthetics Inc (ZLTQ): Aisling Capital’s Winning Plays in Small-Cap Healthcare Stocks

Page 1 of 2

On Tuesday, Esperion Therapeutics Inc (NASDAQ:ESPR)‘s stock closed the trading section as one of the market leaders, ending the day up by 29%. The jump came on the back of positive results from the company’s ETC-1002-009 Phase b2 study, which evaluated the efficacy and safety of ETC-1002 (bempedoic acid) in patients with hypercholesterolemia on stable statin therapy. The news have definitely pleased investors that were betting on the company. One of them is Dennis Purcell of Aisling Capital, who invested more than 12% of his fund’s equity portfolio in Esperion, the holding being the largest in the fund’s equity portfolio. At the end of 2014, Aisling held 2.05 million shares of Esperion Therapeutics, the value of the stake amounting to $83.09 million. As the stock gained over 140% since the beginning of the year, Aisling’s stake is currently valued at $198.23 million.

Esperion Therapeutics

Esperion Therapeutics Inc (NASDAQ:ESPR)’s top-line results in a 12-week study, demonstrated an up to 30% reduction in high-sensitivity C-reactive protein from ETC-1002. Therefore, the study met its primary endpoint of greater LDL-cholstrol lowering from baseline with ETC-1002 compared with placebo. Aside from the study results, the company also announced an underwritten public offering, during which it plans to sell $150 million worth of stock and $22.5 million of stock as over-allotment options.

As Esperion Therapeutics Inc (NASDAQ:ESPR) was conducting its study, investors became more and more confident about the company’s prospects and the number of funds holding shares of the company among those that we track, surged to 14 from 5 a quarter earlier. Moreover, the aggregate value of the positions in Esperion held by the funds that we track jumped to $197.39 million, from $80.10 million in the previous quarter. Another investor bullish on the company is Matthew Halbower of Pentwater Capital Management, which owns 1.47 million shares as of the end of 2014, up by 49% on the quarter. However, other investors own less significant stakes in the company.

Aisling Capital is a healthcare-focused hedge fund that held around $659.64 million in assets. Due to the fund’s small equity portfolio and focus on healthcare picks, it makes sense that the fund invests in a range of small-cap companies, which are more likely to be trading at a discount or are still at the development stage. Investing in small-cap healthcare picks pays off big time for Aisling Capital, as we will see next, when we take a look at the fund’s other top holdings. In this way, following Aisling’s activity as well as other hedge funds that invest in small-cap stocks might be profitable for smaller investors looking to beat the market. We have analyzed the data from 13F filings between 1999 and 2012 among the hedge funds that we track and determined that a portfolio consisting of 15 most popular small-cap picks among hedge funds can beat the market by 1 percentage point per month. Since we have been sharing these 15 stocks in our newsletters, in August 2012, our strategy generated a cumulative return of over 131% in 2.5 years, while the S&P 500 ETS (SPY) appreciated by some 57.2%.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!